Drug Development

Our firm is consistently ranked as the leading practice in Israel in the representation of drug development and pharma companies. We have been representing companies in this sector since 1993.

We represent many dozens of companies that develop drugs, from their start-up phase, through the many years of research and development activities, clinical trials, regulatory pathways and distribution, and marketing arrangements. Our clients develop cures for orphan diseases of all kinds, for cancer, for skin related ailments, and for cosmetic purposes. We also represent the leading venture capital fund in this sector – Pontifax Ventures – including the incorporation of several funds, and their ongoing representation both in new investments and loans, and in the oversight of portfolio companies.

We represent our clients in transactions including:

• Licensing and development;
• Collaboration agreements;
• Clinical trial agreements;
• Agreements with clinical research organizations (CROs);
• Agreements with clinical and regulatory advisors;
• Supply and manufacturing agreements; and
• Commercialization agreements, including distribution, resale, and sublicense agreements.

These transactions require an understanding of issues and market standards relating to liability, privacy, insurance and quality of care. Our firm is considered to be at the cutting edge of these standards.

Our understanding of the boundaries of liability in these matters facilitates our advice on the wide range of corporate and financing matters faced by companies in this space:

• Funding by venture capital funds, institutions, government and angels;
• GDPR and privacy analysis under Israeli law;
• Employment, and consultancy agreements, benefit plans;
• General corporate and commercial advice; and
• Exit strategies, including asset sales, exclusive licenses, IPOs, and M&As.